The University of Chicago Header Logo

Connection

James Vardiman to Middle Aged

Back to Details
This is a "connection" page, showing publications James Vardiman has written about Middle Aged.
James Vardiman
Connection Strength
0.323
Middle Aged
  1. A subset of Rosai-Dorfman disease exhibits features of IgG4-related disease. Am J Clin Pathol. 2013 May; 139(5):622-32.
    View in: PubMed
    Score: 0.029
  2. Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. Leukemia. 2013 Jun; 27(6):1291-300.
    View in: PubMed
    Score: 0.028
  3. The Conundrum of Diagnosing Cutaneous Composite Lymphoma in the Molecular Age. Am J Dermatopathol. 2019 Oct; 41(10):757-766.
    View in: PubMed
    Score: 0.011
  4. Morphologic bone marrow changes in patients with posttransplantation lymphoproliferative disorders. Am J Surg Pathol. 1998 Feb; 22(2):208-14.
    View in: PubMed
    Score: 0.010
  5. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996 Jan; 10(1):20-6.
    View in: PubMed
    Score: 0.009
  6. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr; 9(4):628-33.
    View in: PubMed
    Score: 0.008
  7. Hodgkin's disease associated with chronic lymphocytic leukemia. Eight additional cases, including two of the nodular lymphocyte predominant type. Am J Clin Pathol. 1995 Apr; 103(4):479-84.
    View in: PubMed
    Score: 0.008
  8. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994 May 15; 83(10):2931-8.
    View in: PubMed
    Score: 0.008
  9. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
    View in: PubMed
    Score: 0.008
  10. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol. 1993 Apr; 99(4):513-25.
    View in: PubMed
    Score: 0.007
  11. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood. 1993 Mar 15; 81(6):1580-5.
    View in: PubMed
    Score: 0.007
  12. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.007
  13. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
    View in: PubMed
    Score: 0.006
  14. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9.
    View in: PubMed
    Score: 0.006
  15. Chromosome abnormalities in B cell chronic lymphocytic leukemia and their clinical correlations. Leukemia. 1989 Mar; 3(3):182-91.
    View in: PubMed
    Score: 0.005
  16. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
    View in: PubMed
    Score: 0.005
  17. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood. 1988 Oct; 72(4):1333-9.
    View in: PubMed
    Score: 0.005
  18. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1770-5.
    View in: PubMed
    Score: 0.005
  19. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
    View in: PubMed
    Score: 0.005
  20. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
    View in: PubMed
    Score: 0.004
  21. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 01; 108(5):1677-83.
    View in: PubMed
    Score: 0.004
  22. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
    View in: PubMed
    Score: 0.004
  23. Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia. Am J Clin Pathol. 1986 Feb; 85(2):194-201.
    View in: PubMed
    Score: 0.004
  24. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.004
  25. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
    View in: PubMed
    Score: 0.004
  26. Autopsy findings in hairy cell leukemia. Semin Oncol. 1984 Dec; 11(4):370-80.
    View in: PubMed
    Score: 0.004
  27. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.004
  28. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
    View in: PubMed
    Score: 0.004
  29. A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). Am J Clin Pathol. 1984 Jun; 81(6):733-41.
    View in: PubMed
    Score: 0.004
  30. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48.
    View in: PubMed
    Score: 0.004
  31. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
    View in: PubMed
    Score: 0.004
  32. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88.
    View in: PubMed
    Score: 0.004
  33. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8.
    View in: PubMed
    Score: 0.004
  34. Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. Am J Clin Pathol. 1983 May; 79(5):525-30.
    View in: PubMed
    Score: 0.004
  35. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.004
  36. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.
    View in: PubMed
    Score: 0.004
  37. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood. 1983 Feb; 61(2):349-52.
    View in: PubMed
    Score: 0.004
  38. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
    View in: PubMed
    Score: 0.003
  39. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14.
    View in: PubMed
    Score: 0.003
  40. Prognostic significance of posttransfusion hepatitis and chromosomal abnormalities in adult acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1982 Apr; 5(4):281-92.
    View in: PubMed
    Score: 0.003
  41. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981 Oct; 58(4):759-67.
    View in: PubMed
    Score: 0.003
  42. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9.
    View in: PubMed
    Score: 0.003
  43. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 01; 19(9):2482-92.
    View in: PubMed
    Score: 0.003
  44. Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol. 1981; 11(1):29-45.
    View in: PubMed
    Score: 0.003
  45. Hairy cell leukemia: an autopsy study. Cancer. 1979 Apr; 43(4):1339-49.
    View in: PubMed
    Score: 0.003
  46. Hairy cell leukemia: diagnosis and management. CA Cancer J Clin. 1978 Sep-Oct; 28(5):265-77.
    View in: PubMed
    Score: 0.003
  47. Acute nonlymphocytic leukemia in malignant lymphoma: a morphologic study. Cancer. 1978 Jul; 42(1):229-42.
    View in: PubMed
    Score: 0.003
  48. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
    View in: PubMed
    Score: 0.003
  49. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996 May 15; 87(10):4076-81.
    View in: PubMed
    Score: 0.002
  50. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.002
  51. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993 Aug 01; 82(3):737-43.
    View in: PubMed
    Score: 0.002
  52. Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia. Br J Haematol. 1993 Mar; 83(3):519-20.
    View in: PubMed
    Score: 0.002
  53. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.002
  54. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood. 1992 Nov 15; 80(10):2463-70.
    View in: PubMed
    Score: 0.002
  55. Expression of the IFN alpha receptor in hairy cell leukaemia. Br J Haematol. 1992 Nov; 82(3):541-6.
    View in: PubMed
    Score: 0.002
  56. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. Br J Haematol. 1991 Nov; 79(3):390-7.
    View in: PubMed
    Score: 0.002
  57. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.002
  58. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.001
  59. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Aug 02; 81(15):1172-4.
    View in: PubMed
    Score: 0.001
  60. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer. 1988 Dec 01; 62(11):2420-4.
    View in: PubMed
    Score: 0.001
  61. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988 Nov; 6(11):1714-21.
    View in: PubMed
    Score: 0.001
  62. A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1988 Oct 15; 35(2):143-50.
    View in: PubMed
    Score: 0.001
  63. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia. 1988 Feb; 2(2):79-83.
    View in: PubMed
    Score: 0.001
  64. The role of interferon in the treatment of hairy cell leukemia. Semin Oncol. 1986 Sep; 13(3 Suppl 2):21-8.
    View in: PubMed
    Score: 0.001
  65. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol. 1986 Jun; 4(6):900-5.
    View in: PubMed
    Score: 0.001
  66. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986 Jun; 67(6):1765-72.
    View in: PubMed
    Score: 0.001
  67. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med. 1986 May; 80(5):891-6.
    View in: PubMed
    Score: 0.001
  68. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
    View in: PubMed
    Score: 0.001
  69. Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL. Am J Hematol. 1985 Apr; 18(4):393-403.
    View in: PubMed
    Score: 0.001
  70. Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood. 1985 Mar; 65(3):644-8.
    View in: PubMed
    Score: 0.001
  71. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984 May; 76(5):827-41.
    View in: PubMed
    Score: 0.001
  72. The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet. 1983 Nov; 10(3):219-36.
    View in: PubMed
    Score: 0.001
  73. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983 Sep 15; 309(11):630-6.
    View in: PubMed
    Score: 0.001
  74. Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation. Cancer Genet Cytogenet. 1983 Feb; 8(2):107-15.
    View in: PubMed
    Score: 0.001
  75. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood. 1982 Aug; 60(2):404-11.
    View in: PubMed
    Score: 0.001
  76. Multiple histologic subtypes of non-Hodgkin's lymphoma: clinical and pathologic features. Cancer. 1981 Nov 01; 48(9):2063-9.
    View in: PubMed
    Score: 0.001
  77. Hairy cell leukemia in father and son. Cancer. 1981 Oct 15; 48(8):1825-9.
    View in: PubMed
    Score: 0.001
  78. Human T-cell lymphoma with suppressor effects on the mixed lymphocyte reaction (MLR). I. Morphological and cytogenetic analysis. Blood. 1981 Apr; 57(4):634-41.
    View in: PubMed
    Score: 0.001
  79. Surface immunoglobulin, lectin-induced cap formation, and phagocytic function in five patients with the leukemic phase of hairy cell leukemia. Cancer. 1980 Jul 01; 46(1):50-5.
    View in: PubMed
    Score: 0.001
  80. Dysmyelopoietic syndrome: sequential clinical and cytogenetic studies. Blood. 1980 Apr; 55(4):636-44.
    View in: PubMed
    Score: 0.001
  81. Evolution of karyotypes in acute nonlymphocytic leukemia. Cancer Res. 1979 Sep; 39(9):3619-27.
    View in: PubMed
    Score: 0.001
  82. Evolution of karyotypes in Philadelphia (Ph1) chromosome-negative chronic myelogenous leukemia. Cancer. 1979 Feb; 43(2):411-6.
    View in: PubMed
    Score: 0.001
  83. Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977). N Engl J Med. 1978 Sep 21; 299(12):613-9.
    View in: PubMed
    Score: 0.001
  84. Hairy cell leukaemia: evidence for the existence of a spectrum of functional characteristics. Br J Haematol. 1978 Feb; 38(2):161-70.
    View in: PubMed
    Score: 0.001
  85. Acute nonlymphocytic leukemia in adults: correlations with Q-banded chromosomes. Blood. 1976 Jul; 48(1):9-21.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.